Hong Kong King-Friend Industrial Company Limited announced that it will receive $21 million in an equity round of funding from returning investor Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd on July 14, 2022. On closing, the investor retains its 100% stake in the company. The transaction has been approved by board of directors of investor in its fifteenth Meeting of the fourth Board of Directors.